112 related articles for article (PubMed ID: 21508397)
1. Impact of renal failure on the tumor markers of mesothelioma, N-ERC/mesothelin and osteopontin.
Shiomi K; Shiomi S; Ishinaga Y; Sakuraba M; Hagiwara Y; Miyashita K; Maeda M; Suzuki K; Takahashi K; Hino O
Anticancer Res; 2011 Apr; 31(4):1427-30. PubMed ID: 21508397
[TBL] [Abstract][Full Text] [Related]
2. ERC/mesothelin as a marker for chemotherapeutic response in patients with mesothelioma.
Tajima K; Hirama M; Shiomi K; Ishiwata T; Yoshioka M; Iwase A; Iwakami S; Yamazaki M; Toba M; Tobino K; Sugano K; Ichikawa M; Hagiwara Y; Takahashi K; Hino O
Anticancer Res; 2008; 28(6B):3933-6. PubMed ID: 19192652
[TBL] [Abstract][Full Text] [Related]
3. Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma.
Shiomi K; Hagiwara Y; Sonoue K; Segawa T; Miyashita K; Maeda M; Izumi H; Masuda K; Hirabayashi M; Moroboshi T; Yoshiyama T; Ishida A; Natori Y; Inoue A; Kobayashi M; Sakao Y; Miyamoto H; Takahashi K; Hino O
Clin Cancer Res; 2008 Mar; 14(5):1431-7. PubMed ID: 18316566
[TBL] [Abstract][Full Text] [Related]
4. Molecular tumor markers for asbestos-related mesothelioma: serum diagnostic markers.
Maeda M; Hino O
Pathol Int; 2006 Nov; 56(11):649-54. PubMed ID: 17040286
[TBL] [Abstract][Full Text] [Related]
5. Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels.
Rai AJ; Flores RM; Mathew A; Gonzalez-Espinoza R; Bott M; Ladanyi M; Rusch V; Fleisher M
Clin Chem Lab Med; 2010 Feb; 48(2):271-8. PubMed ID: 20131968
[TBL] [Abstract][Full Text] [Related]
6. Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma.
Hollevoet K; Nackaerts K; Gosselin R; De Wever W; Bosquée L; De Vuyst P; Germonpré P; Kellen E; Legrand C; Kishi Y; Delanghe JR; van Meerbeeck JP
J Thorac Oncol; 2011 Nov; 6(11):1930-7. PubMed ID: 21841505
[TBL] [Abstract][Full Text] [Related]
7. MESOMARK kit detects C-ERC/mesothelin, but not SMRP with C-terminus.
Segawa T; Hagiwara Y; Ishikawa K; Aoki N; Maeda M; Shiomi K; Hino O
Biochem Biophys Res Commun; 2008 May; 369(3):915-8. PubMed ID: 18328258
[TBL] [Abstract][Full Text] [Related]
8. Mesothelin and kidney function--analysis of relationship and implications for mesothelioma screening.
Boudville N; Paul R; Robinson BW; Creaney J
Lung Cancer; 2011 Sep; 73(3):320-4. PubMed ID: 21333373
[TBL] [Abstract][Full Text] [Related]
9. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.
Grigoriu BD; Scherpereel A; Devos P; Chahine B; Letourneux M; Lebailly P; Grégoire M; Porte H; Copin MC; Lassalle P
Clin Cancer Res; 2007 May; 13(10):2928-35. PubMed ID: 17504993
[TBL] [Abstract][Full Text] [Related]
10. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
Pass HI; Wali A; Tang N; Ivanova A; Ivanov S; Harbut M; Carbone M; Allard J
Ann Thorac Surg; 2008 Jan; 85(1):265-72; discussion 272. PubMed ID: 18154821
[TBL] [Abstract][Full Text] [Related]
11. Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden.
Creaney J; Francis RJ; Dick IM; Musk AW; Robinson BW; Byrne MJ; Nowak AK
Clin Cancer Res; 2011 Mar; 17(5):1181-9. PubMed ID: 21177406
[TBL] [Abstract][Full Text] [Related]
12. Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma.
Cristaudo A; Bonotti A; Simonini S; Vivaldi A; Guglielmi G; Ambrosino N; Chella A; Lucchi M; Mussi A; Foddis R
J Thorac Oncol; 2011 Sep; 6(9):1587-93. PubMed ID: 21642872
[TBL] [Abstract][Full Text] [Related]
13. Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary study.
Bruno F; Baratti D; Martinetti A; Morelli D; Sottotetti E; Bonini C; Guaglio M; Kusamura S; Deraco M
Eur J Surg Oncol; 2018 Jun; 44(6):792-798. PubMed ID: 29503128
[TBL] [Abstract][Full Text] [Related]
14. Does CA125 binding to mesothelin impact the detection of malignant mesothelioma?
Creaney J; Dick IM; Dare H; Demelker Y; Nowak AK; Musk AW; Robinson BW
Lung Cancer; 2013 Apr; 80(1):39-44. PubMed ID: 23357461
[TBL] [Abstract][Full Text] [Related]
15. Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma.
Wheatley-Price P; Yang B; Patsios D; Patel D; Ma C; Xu W; Leighl N; Feld R; Cho BC; O'Sullivan B; Roberts H; Tsao MS; Tammemagi M; Anraku M; Chen Z; de Perrot M; Liu G
J Clin Oncol; 2010 Jul; 28(20):3316-22. PubMed ID: 20498407
[TBL] [Abstract][Full Text] [Related]
16. Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma--which is best?
Creaney J; Yeoman D; Musk AW; de Klerk N; Skates SJ; Robinson BW
Lung Cancer; 2011 Oct; 74(1):55-60. PubMed ID: 21397972
[TBL] [Abstract][Full Text] [Related]
17. Circulating levels of osteopontin are closely related to glomerular filtration rate and cardiovascular risk markers in patients with chronic kidney disease.
Lorenzen J; Krämer R; Kliem V; Bode-Boeger SM; Veldink H; Haller H; Fliser D; Kielstein JT
Eur J Clin Invest; 2010 Apr; 40(4):294-300. PubMed ID: 20486990
[TBL] [Abstract][Full Text] [Related]
18. Secretion of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma.
Inami K; Kajino K; Abe M; Hagiwara Y; Maeda M; Suyama M; Watanabe S; Hino O
Oncol Rep; 2008 Dec; 20(6):1375-80. PubMed ID: 19020717
[TBL] [Abstract][Full Text] [Related]
19. Establishment of novel mAb to human ERC/mesothelin useful for study and diagnosis of ERC/mesothelin-expressing cancers.
Ishikawa K; Segawa T; Hagiwara Y; Maeda M; Abe M; Hino O
Pathol Int; 2009 Mar; 59(3):161-6. PubMed ID: 19261093
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.
Rodríguez Portal JA; Rodríguez Becerra E; Rodríguez Rodríguez D; Alfageme Michavila I; Quero Martínez A; Diego Roza C; León Jiménez A; Isidro Montes I; Cebollero Rivas P
Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):646-50. PubMed ID: 19190155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
